Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Crowell & Moring says it examined SEC-FDA information sharing and company disclosures
Crowell & Moring said it published an analysis of the SEC and FDA’s memorandum on sharing nonpublic information concerning FDA-regulated products and businesses. The firm’s client alert considered the implications for life sciences and healthcare companies preparing investor disclosures and coordinating their regulatory, securities and compliance functions.
Key points
- Crowell discussed cross-checking investor disclosures against FDA communications and records.Crowell & Moring
- The firm examined confidentiality protections and responses to requests for shared information.Crowell & Moring
- Crowell addressed disclosures by companies preparing for initial public offerings.Crowell & Moring
- The firm considered insider trading policies and coordination between regulatory affairs teams and securities counsel.Crowell & Moring